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Abstract: MUTYH Associated Polyposis (MAP), a Polyposis predisposition caused by biallelic mutations in the Base Ex-
cision Repair (BER) gene MUTYH, confers a marked risk of colorectal cancer (CRC). The MAP phenotype is difficult to 
distinguish from other hereditary CRC syndromes. Especially from Familial Adenomatous Polyposis (FAP) and to a 
lesser extend Lynch Syndrome, which are caused by germline mutations in the APC and Mismatch Repair (MMR) genes, 
respectively.  
Here we review research findings regarding MUTYH interactions, genotypic and phenotypic characteristics of MAP, as 
well as surveillance and treatment of the disease. The applied papers, published between 1/1 2002- 1/2 2008, were found 
through PubMed. 
The exact role of MUTYH in CRC tumorgenesis is still uncertain, although MAP tumors show distinct molecular features, 
including somatic G:C>T:A transversions in the APC gene. Furthermore, cooperation between the BER and the MMR 
systems exists, as MUTYH interacts with MMR gene-products. Possibly, monoallelic defects in both pathways are of sig-
nificance to CRC development.  
Specific MUTYH variants are found to be characteristic in distinct ethnic populations, which could facilitate future genetic 
screening. Knowledge concerning functional consequences of many MUTYH germline mutations remains sparse. Most 
thoroughly investigated are the two most common MUTYH variants, Y179C and G396D, both generating dysfunctional 
gene products. 
Phenotypic features of MAP include: development of 10-100 colorectal adenomas, debuting at 46-47 years, often CRC at 
time of clinical diagnosis, and in some, development of extracolonic manifestations.  
Received on: April 18, 2008 - Revised on: April 28, 2008 - Accepted on: May 4, 2008 
Key Words: Colorectal cancer, MUTYH associated polyposis, The MUTYH gene, base excision repair, (Attenuated) familial 
adenomatous polyposis, lynch syndrome.  
INTRODUCTION 
  Colorectal Cancer (CRC) is the second most prevalent 
cancer worldwide [1]. In 35% of CRC patients, statistically 
significant effects of hereditary factors have been found [2]. 
For some of these patients the genetic background is known; 
major CRC syndromes being: Lynch Syndrome, Familial 
Adenomatous Polyposis (FAP) and MUTYH Associated 
Polyposis (MAP), which will be focused on in this review. 
Fig. (1) shows a delimitation of the groups of patients, which 
are referred to in this paper. 
  Lynch Syndrome is characterized by the development of 
particularly CRC and endometrial cancer at a young age. 
Lynch Syndrome is an autosomal dominant disease often 
caused by germline mutations in one of the Mismatch Repair 
(MMR) genes [3, 5-7]. The clinical and genetic features of 
the syndrome have previously been thoroughly reviewed in 
[5-9].  
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  Another autosomal dominant disease, Familial Adenoma-
tous Polyposis (FAP), is caused by a germline mutation in 
the APC gene, and confers a near 100% risk of developing 
CRC. FAP has been shown to account for less than 0.1% of 
all CRC cases [10]. The characterization of the APC gene 
and protein-product has been repeatedly reviewed, among 
others in [11] and [12]. Phenotypic characteristics of FAP 
include: early development of more than 100 and up to thou-
sands of colorectal adenomas, as well as extracolonic mani-
festations such as gastric and duodenal adenomas, desmoid 
tumors and congenital hypertrophy of the retinal pigment 
epithelium (reviewed in [8, 13-16]). In FAP, genotype-pheno-  
type correlations have been identified, specific APC gene 
mutations being associated with particular manifestations 
reviewed in [11] and [17]. Of particular clinical interest is 
the milder phenotypical FAP variant, Attenuated Familial 
Adenomatous Polyposis (AFAP), which is associated with 
APC mutations in the extreme ends of, or in the alternatively 
spliced region of exon 9 [11, 18]. AFAP is distinguished 
from FAP by the development of less than 100 colorectal 
adenomas, fewer extracolonic manifestations and the later 
development of CRC [11, 13-16, 19]. One study showed that 
about 8% of registered FAP families present with an AFAP 
phenotype [19].  MUTYH Associated Polyposis (MAP)  Current Genomics, 2008, Vol. 9, No. 6    421 
  Prophylactic screening of Lynch Syndrome patients, FAP 
patients and their families is shown to reduce the develop-
ment of CRC and CRC-associated mortality markedly [5, 9, 
10, 13, 16, 20]. For Lynch Syndrome patients, the recom-
mendation is colonoscopy from about 20-25 years of age, in 
intervals of 1-3 years [5, 7, 9, 20]. The benefit of screening 
for endometrial cancer and other cancers associated with 
Lynch Syndrome is still controversial, and recommendations 
should be adjusted according to the individual patient’s 
wishes, family history and possibly genotype [7, 9, 20].  
  Recommendations for FAP surveillance was recently 
reviewed in [13] and [16]. Sigmoidoscopy is advised to FAP 
patients commencing in the early teens, typically in intervals 
of 1-3 years, according to the clinical manifestations [13, 15, 
16]. Furthermore, individual assessment is especially neces-
sary in FAP families displaying a more severe phenotype 
[16]. Additionally, FAP patients should be offered endo-
scopy of the upper gastrointestinal tract from the age of 
about 25-30 years, in intervals of 1-5 years, according to the 
severity of duodenal Polyposis [16]. Moreover, prophylactic 
colectomy is often advisable for FAP patients. Especially in 
patients with an early first appearance of the disease, the 
surgical procedure recommended varies between the indi-
vidual FAP patients [13, 15, 16]. For AFAP patients, colo-
scopy in intervals of 2 years is advised starting from 18-20 
years of age, due to the later CRC development and the typi-
cally more distal location of adenomas in AFAP patients 
compared to FAP patients [16, 19].  
  In as many as 30% of patients with a FAP-like pheno-
type, no germline mutations in the APC gene can be found 
[15]. Similarly, one study of patients with an AFAP-like 
phenotype (3-100 adenomas), found that merely about 10% 
of these patients had inherited germline APC mutations [18]. 
However, another study (N=59) showed that almost 70% of 
patients with an AFAP-like phenotype (10-100 adenomas) 
had a germline APC mutation [19]. 
  In 2002, the significance of mutations in the MUTYH 
gene regarding the development of the Polyposis predisposi-
tion syndrome MUTYH Associated Polyposis (MAP) was 
discovered [21]. Since then, many aspects of MAP have 
been investigated, and the important question of how, these 
new discoveries can be used in the genetic counseling and 
screening of individuals at risk of developing MAP, now 
stands to be answered.  
  Here we review the main genetic aspects of MAP, in-
cluding analysis of functional consequences and the outlin-
ing of specific ethnic allelic frequencies of MUTYH variants. 
In addition, we review the clinical aspects of the syndrome 
and introduce a new nomenclature for MUTYH  germline 
mutations, which is likely to replace the nomenclature, 
which is currently used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Delimitation of the groups of patients. 
synchronous occurrence of Polyposis. a gen 
The following groups of patients are defined on the basis of both clinical and genetic characteristics, 
and will be referred to throughout the text. 
 
On a clinical basis:  
 
Polyposis patients:  Patients presenting with adenomas in the colon and/or rectum. 
 
CRC patients:   Patients presenting with carcinomas in the colon and/or rectum, 
with or without previous/synchronous occurrence of Polyposis. 
 
MAP patients: (OMIM  608456) 
Polyposis patients with detected biallelic germline mutations in 
the MUTYH gene. 
 
On a mixture of clinical and genetic basis: 
 
FAP patients: (OMIM  175100) 
Polyposis patients presenting with > 100 adenomas in the colon 
and/or rectum and – in this paper - with a detected germline 
mutation in the APC gene. 
 
AFAP patients: (OMIM 175100)  
Polyposis patients presenting with < 100 adenomas in the colon 
and/or rectum. (Possibly with a detected germline mutation in the 
APC gene). 
 
Lynch Syndrome patients  
(Previously known as HNPCC (Hereditary Non-Polyposis Colorectal Cancer  
patients): (OMIM: HNPCC1: 120435, HNPCC2: 609310) 
Several guidelines for the clinical diagnosis of these patients exist 
(e.g. The Amsterdam criteria I and II [3] and the Bethesda criteria 
[4]). Familial disposition for CRC, possibly with a detected 
germline mutation in a Mismatch Repair (MMR) gene. 
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  We believe that this review provides a broad, up-to-date 
overview of existing findings regarding MAP. We hope to 
provide perspective of the significance of MUTYH, as well 
as of which issues regarding MAP call for future investiga-
tion. 
PATHOGENESIS OF MAP: THE MUTYH GENE AND 
BASE EXCISION REPAIR 
Base Excision Repair 
 The  MUTYH gene product is part of the Base Excision 
Repair (BER) system, which serves as an important part of 
cells´ defense against oxidative damage to the DNA. The 
BER system and the functional role of MUTYH have previ-
ously been reviewed in detail by [22-31].  
  Oxidative DNA damage, caused by reactive oxygen spe-
cies (ROS), which are produced during aerobic metabolism, 
exposure to certain chemicals or radiation, constantly threat-
ens the integrity of cellular DNA. The oxidized base 7,8-
dihydroxy-8-oxoguanine (8-oxo-G) is one of the most stable 
and mutagenic products of oxidative DNA damage. 8-oxo-G 
is often mistakenly paired with adenine (A), resulting in the 
appearance of Guanine:Cytosine > Thymidine:Adenine (G:C 
> T:A) transversions at the next round of DNA replication, 
as the detection of stable 8-oxo-G:A base-pairs is missed by 
the replicative DNA polymerases [22-31].  
  The human DNA-damage-specific glycosylases OGG1, 
MUTYH and MTH1, which are central enzymes in the BER 
pathway, function by specifically recognizing and facilitat-
ing the removal of 8-oxo-G [23-31]. The specific mechanism 
of recognition of the DNA-damage-specific glycosylases is 
characterized as “base-flipping”, involving the outwards 
rotation of nucleotides from the DNA helix. This allows the 
incorporated bases to be assessed by fitting into base-specific 
pockets of the glycosylases [22, 23, 26, 29-32]. The repair 
process at the damaged site is subsequently completed by the 
synthesis and incorporation of newly replicated DNA, in-
volving several repair steps, which are facilitated by a se-
quence of DNA repair enzymes [23, 25, 26, 28-30]. The 
MUTYH glycosylase acts as the third level of BER, as it 
postreplicativly excises the misincorporated A opposite 8-
oxo-G [23-25, 29-31]. For this reason, defective MUTYH 
function is associated with an increased frequency of G:C > 
T:A transversions [29]. Inactivation of MUTYH has accord-
ingly been associated with various cancer forms [29], includ-
ing lung cancer, gastric cancer, CRC [25, 33-36] and re-
cently also endometrial cancer [37]. 
  A number of studies of the human MUTYH glycosylase, 
both in vitro and in vivo, have demonstrated that the MU-
TYH glycosylase directly interacts with various proteins 
involved in other DNA repair pathways (reviewed by [29] 
and [31]). 
  Several studies have also screened the OGG1 and MHT1 
genes in Polyposis patients without any significant findings 
of association with Polyposis or CRC phenotypes. [21, 38-
41]. However, OGG1  variants have recently been demon-
strated to be significantly associated with a multiple ade-
noma phenotype [42] and the development of sporadic CRC 
[43], although the latter association was of borderline sig-
nificance and should be further investigated [43]. This re-
view focuses exclusively on the significance of MUTYH mu-
tations in relation to MAP and CRC. 
THE MUTYH GENE 
  The MUTYH glycosylase is encoded by the MUTYH 
gene, located on the short arm of chromosome 1 (1p32.1-
p34.3). The gene consists of 16 exons and encodes a protein 
of 535 amino acids, the MUTYH glycosylase. Characteriza-
tion of the MUTYH gene and functional variants has been 
reviewed in [22-26, 29].  
  Exon 3 in MUTYH is alternatively spliced in various 
ways, generating different MUTYH transcripts [25, 29, 44]. 
In accordance with HGVS nomenclature rules, the longest 
MUTYH transcript existing (NM_012222.2 extended at the 
5´of exon 3) will be used as coding DNA reference se-
quence, as outlined by Leiden Open Variation Database 
(LOVD) at http://www.LOVD.nl/MUTYH [44]. The use of 
the longest existing MUTYH transcript as coding DNA refer-
ence sequence is predicted to replace the previous commonly 
used  MUTYH transcript (NM_001048171), although many 
authors still refer to this. Also, experts in this field (J. Samp-
son, F. Hes and S. Aretz) have recently discussed the use of 
MUTYH reference sequence. They agree that NM_012222.2 
extended at 5´of exon 3 is the best option to use as reference 
sequence in the future [45].  
  Consequently, the amino acid numbering in this paper 
differs from the one used in many previous papers. An over-
view of the new and old terms regarding some of the most 
common MUTYH mutations mentioned in this paper can be 
found in Table 1.  
DEVELOPMENT OF COLORECTAL ADENOMAS 
AND CRC TUMORGENESIS IN MAP 
  Somatic mutations in the APC gene are important in CRC 
tumorgenesis due to the gatekeeper role of the APC tumor 
suppressor gene, which is involved in many cellular proc-
esses. (Reviewed in [11] and [12].) The development of co-
lorectal adenomas is likely to be initiated by an APC gene 
left dysfunctional as a result of germline or somatic muta-
tions [11].  
 Defects  in  the  MUTYH gene were first shown to be asso-
ciated with a Polyposis predisposition by Al Tassan et al. in 
2002 [21]. Defects in the BER genes were suspected, when 
11 tumors from 3 related Polyposis patients showed somatic 
mutations in the APC gene, consistent with a defective BER 
system, while no germline APC mutations were found [21]. 
  The cause as to why, mutations in the MUTYH gene pre-
dispose to the development of colorectal adenomas in par-
ticular, has not yet been fully determined. However, the 
number of spontaneous somatic C:G > T:A transversions in 
the APC gene is significantly greater in tumor cells with bial-
lelic MUTYH germline mutations compared to tumor cells 
without MUTYH mutations [21, 38, 40, 46, 47].  
  The DNA sequence adjacent to the sites of G:C > T:A 
transversions in the 3’ end of the APC gene appears to be of 
significance to the specificity of the MUTYH glycosylase. A 
significantly higher occurrence of GAA sites has repeatedly 
been demonstrated 3’ to the G:C > T:A transversions, thus 
creating stop codons, and resultantly a truncated APC pro-MUTYH Associated Polyposis (MAP)  Current Genomics, 2008, Vol. 9, No. 6    423 
tein. These results are seen even though the G:C > T:A 
transversions theoretically could occur at any other G:C site 
in the APC gene [21, 38, 48]. Also, in vitro experiments with 
E. coli MutY have revealed a pronounced sequence prefer-
ence for MutY to GAA [49]. However, the significance of 
these findings and the question as to why GAA sites seem to 
be prone to G:C > T:A transversions, remain unclear and call 
for further investigations.  
  Both the high number of GAA sites in the APC gene 
compared to other key tumorgenesis genes frequently in-
volved in other cancers [23], as well as the considerable ex-
posure to ROS in the gastrointestinal tract, could be part of 
the explanation of why germline MUTYH mutations, and 
subsequently somatic APC mutations, are associated with 
development of particularly CRC [23]. 
  Characteristic molecular profiles of colorectal tumors, 
both adenomas and carcinomas, taken from MAP patients 
have been found [46, 50]. Distinct features of MAP tumors 
include: C:G > T:A transversions in the APC gene and the 
proto-oncogene  K-Ras [46, 50]. Comparable with somatic 
APC mutations, statistically significant numbers of somatic 
mutations in the K-Ras gene have been found in MAP tu-
mors, compared to tumors without MUTYH mutations [47, 
50]. The described K-Ras mutations have all been identical 
G > C transversions in codon 12, G12C [46, 47].  
Table 1.  Overview of Nomenclature for MUTYH Germline Mutations 
Nomenclature from Reference Sequence NM_ 001048171  Nomenclature from Reference Sequence NM_012222.2  
(Extended at the 5’ end of exon 3)* 
p.V22M   p.V22M 
p.Y90X p.Y104X 
p.Y114H p.Y128H 
p. Y165C  p.Y179C 
p.R168H   p.R182H 
p.R168C p.R182C 
p.R171Q p.R185Q 
p.G175E p.G189E 
p.R227W p.R241W 
p.R231C   p.R245C 
p.V232F p.V246F 
p.Q324H p.Q338H 
p.E369fsX437 p.E383fsX451 
p. G382D  p. G396D 
p.P391L p.P405L 
p.A459D p.A473D 
p.E466X p.E480X 
p.S501F p.S515F 
c.934-2A>G c.976-2A>G 
c.1391delAGG   c.1433delAGG 
c.1103delGGA c.1145delGGA 
c.1395delGGA   c.1437delGGA  
c.1103delC c.1145delC 
c.1186_1187insGG   c.1228_1229dupGG 
c.IVS10-2A>G   c.IVS10-2A>G 
*The new nomenclature for MUTYH mutations is based on referral to the longest existing MUTYH transcript and were found at http://www.LOVD.nl/MUTYH 424    Current Genomics, 2008, Vol. 9, No. 6  Poulsen and Bisgaard 
  Molecular features in MAP tumors are characteristic to 
these, compared to carcinomas from Sporadic CRC, FAP or 
Lynch Syndrome tumors [46], which can potentially be used 
in classification of CRCs [50]. These molecular characteris-
tics of MAP carcinomas include: low MSI (Microsatellite 
instability), low frequencies of APC, -cantenin mutations 
and LOH (Loss of Heterozygosity) of 18q, harboring the 
SMAD4 gene, and the karyotype of tumor cells typically be-
ing near-diploid [46, 50].  
  The issue of a possible significance of the MUTYH gene 
in Sporadic CRC has been only sparsely addressed, and with 
contradictory outcomes. Halford et al. found no indications 
of MUTYH involvement in Sporadic CRC [39]. In contrast, 
somatic mutations in the MUTYH gene have recently been 
demonstrated in Sporadic CRC, indicating a role of the MU-
TYH gene in Sporadic CRC tumorgenesis [51].  
INTERACTION BETWEEN THE MUTYH GENE AND 
THE MISMATCH REPAIR GENES 
  The Mismatch Repair (MMR) system functions pos-
treplicativly correcting DNA errors, which occur during 
DNA replication. The normal MMR function and characteri-
zation of defects in the MMR system have previously been 
reviewed in [7, 29] and [52]. Key proteins in the human 
MMR system include MutL homologs (MTH1 and Pms2) 
and MutS homologs (MSH2, MSH3, MSH6), the latter 
group forming two heterodimeric complexes [7, 29, 52]. 
  Presumably cooperation between the BER and the MMR 
systems exists, since in vitro experiments have shown that 
MUTYH physically interacts with the MSH2/MSH6 het-
erodimeric complex via a hMSH6-binding domain [53, 54]. 
These two studies have further demonstrated, that the 
MSH2/MSH6 complex stimulates the activity of the MU-
TYH glycosylase by enhancing the affinity of MUTYH for 
8-oxo-G:A mismatched base pairs in the DNA [53, 54].  
 Several  MUTYH germline mutations are shown to influ-
ence the interaction between MUTYH and MSH6, followed 
by a massive decrease in activity of the MUTYH protein [54, 
55]. Mutations in one or more of the genes involved in the 
two systems possibly affect the repair of DNA damage 
caused by 8-oxo-G. The importance of this in regard to CRC 
tumorgenesis is still uncertain, although there have been in-
dications, that interaction between a defect MUTYH  gene 
and a defect MMR gene is of significance in regard to CRC 
risk. In a study by Niessen et al. (N=210), a significantly 
higher frequency of carriers of monoallelic MUTYH muta-
tions was found among CRC patients who also had a specific 
MMR mutation (5/36=14%), in comparison to groups of 
CRC patients with other MMR mutations (1/40= 2.5%) or 
without MMR mutations (1/134 =0.7%) [56]. In this study a 
particularly strong association between monoallelic MUTYH 
germline mutations and en missense variant of the MSH6 
gene was found (4/20 = 20%) [56], consistent with the be-
fore mentioned interaction between the two corresponding 
proteins. 
  In contrast, studies of CRC patients have indicated that 
the BER and MMR pathways may be mutually exclusive, 
although none have found significant results [48, 57]. Fur-
thermore, Van Puijenbroek et al. found a remarkably mild 
Polyposis phenotype in a patient both compound heterozy-
gote for MUTYH mutations, as well as being a carrier of a 
MSH6 germline mutation, supporting this notion [58]. How-
ever, these studies do not provide substantial data for any 
conclusions, for which reason further investigations need to 
be carried out. 
ALLELIC FREQUENCIES OF MUTYH GERMLINE 
MUTATIONS IN DIFFERING POPULATIONS 
  An overview of the most commonly identified germline 
mutations in the MUTYH gene to date can be found at the 
LOVD at http://www.LOVD.nl/MUTYH. 
  Specific mutations in the MUTYH gene are found in dif-
ferent populations, see Fig. (2). In European populations the 
two missense mutations Y179C and G396D are most fre-
quently seen, and have solely been found in Caucasians. The 
allelic frequencies of Y179C and G396D found among MAP 
patients are much higher compared to those found in back-
ground populations, see Fig. (3).  
  In Asian populations, Y179C and G396D do not seem to 
be of significance with regard to the development of Poly-
posis, since neither has been found in Asian Polyposis pa-
tients or in the corresponding background populations [42, 
43, 55, 59-61]. In studies of Korean and Japanese Polyposis 
patients (N=97), 7.2% were biallelic carriers of other germ-
line mutations in the MUTYH gene [55, 61]. Other studies of 
Korean and Singaporean Polyposis patients (N= 63) failed to 
find any MUTYH mutations after screening of coding regions 
in the entire gene, although these results may be biased due 
to small sample size [43, 59, 60]. Characteristic mutations 
found in Japanese Polyposis patients include the missense 
mutation R245C and the splice-site mutation IVS10-2A>G, 
neither of which were found in the corresponding back-
ground population [55]. 
  To date, five unrelated Indian MAP patients have been 
identified, all were homozygote for the missense mutation 
E480X [38, 62, 63]. However, in a case-control study of In-
dian Polyposis patients (cases: N=120 and controls: N=100), 
merely one case and one control were found to be heterozy-
gote for E480X, while no other MUTYH  mutations were 
found [64]. These results suggest that MUTYH mutations are 
unlikely to be of significant importance to development of 
Polyposis among Indian individuals. Other MUTYH variants 
found in noteworthy allelic frequencies in characteristic 
populations are: c.1145delC (found in Italian MAP patients 
in allelic frequencies of 0.07-0.11 [65, 66]), A473D (found in 
Finnish Polyposis and CRC patients, in the latter group with 
an allelic frequency of 0.01 [67]) and E383fsX451 (found in 
Portuguese MAP patients with allelic frequencies of 0.15-
0.19 [68, 69]).  
  In addition, other MUTYH polymorphisms without any 
apparent pathogenic importance have been found. The most 
frequent of these are V22M, Q388H and S515F, the allelic 
frequencies of which in healthy control groups are found to 
be equivalent to those found among MAP patients [21, 39-
41, 48, 56, 67, 69-78].  MUTYH Associated Polyposis (MAP)  Current Genomics, 2008, Vol. 9, No. 6    425 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Mean Allelic Frequencies among Carriers of MUTYH Germline Mutations. 
N= Number of biallelic and monoallelic MUTYH germline mutation carriers. Included are mutations which are believed to be of pathogenic significance, and which are 
found with an allelic frequency of > 0,03 in mutation carriers from the respective countries.  
The figure is based on data colleced from the following studies: Al-Tassan et al., 2002; Jones et al., 2002; Sieber et al., 2003; Sampson et al., 2003; Halford et al., 2004; 
Fleischmann et al., 2004; Gismondi et al., 2004; Isidro et al., 2004; Venesio et al., 2004; Wang et al., 2004; Aceto et al., 2005; Kairupan et al., 2005; Miyaki et al., 2005; 
Leite et al., 2005; Aretz et al., 2006; Kanter-Smoler et al., 2006; Niessen et al., 2006; Russel et al., 2006, Ajith Kumar et al., 2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Mean Allelic Frequencies of p. Y179C and p. G396D in Background Populations. 
N= Number of tested individuals. The individuals tested belong to control groups without Polyposis. 
The figure is based on data colleced from the following studies : Al-Tassan et al., 2002; Enholm et al., 2003; Sieber et al., 2003; Croitoru et al., 2004; Isidro et al., 2004; 
Leite et al., Miyaki et al., 2005; Peterlongo et al., 2005; Zhou et al., 2005; Aretz et al., 2006; Kairupan et al., 2005; Kanter-Smoler et al., 2006; Niessen et al., 2006; 
Russel et al., 2006. 426    Current Genomics, 2008, Vol. 9, No. 6  Poulsen and Bisgaard 
 
FUNCTIONAL CONSEQUENCES OF SPECIFIC 
GERMLINE MUTYH MUTATIONS  
  The two most common MUTYH  mutations, the Y179C 
and G396D, are situated in the catalytic and C terminal do-
mains of MUTYH, respectively. Both of these MUTYH 
residues have important roles in the recognition of 8-oxo-G 
in A:8-oxo-G mispairs [31, 32, 49, 79, 80]. Accordingly, 
functional studies of murin variants corresponding to Y179C 
and G396D have indicated compromised substrate recogni-
tion as a consequence of these mutations [81].  
 The  Y179C mutation is located in the N-terminal end of 
the MUTYH, and is part of the pseudo-HhH (helix-hairpin-
helix) motif in the catalytic region of the MUTYH. This re-
gion is thought to promote the base-flipping mechanism in 
substrate recognition, participate in maintaining stability 
during this process, as well as being involved in DNA bind-
ing [30, 49, 79, 82] (thoroughly reviewed in [31]). Studies of 
biallelic Y179C mutations in human cell lines illustrate, that 
defective MUTYH function results from both significantly 
reduced levels of MUTYH protein (Protein levels of 5-10% 
compared to wild-type MUTYH levels) as well as from re-
duced binding and cleavage ability towards the mispaired 
substrates [83].  
 G396D is located in the C-terminal domain of the MU-
TYH, which is thought to be responsible for 8-oxo-G recog-
nition and binding, as well as mediating the base-flipping 
mechanism [31, 32, 49, 79, 80]. Human cell lines with bial-
lelic G396D mutations show defective MUTYH function as 
a result of the production of a dysfunctional protein. The 
protein shows both reduced binding activity of mispaired 
substrates (about 50% of the wild-type MUTYH activity), as 
well as lower rates of repair, compared to the wild type MU-
TYH [83]. However, the MUTYH protein levels in these cell 
lines were found to be equivalent to the levels of wild type 
protein, indicating that protein instability is not a conse-
quence of G396D mutations [83].  
  These results are consistent with previous studies of the 
corresponding E. coli MutY variants, which have been shown 
to severely compromise the activity of the glycosylase [21, 
49]. In one study, the Y179C and G396D variants showed a 
98% and a 86% reduction in adenine removal from a G:A 
substrate, compared to the wild-type protein, respectively 
[21]. Likewise, both MutY variants exhibit significantly re-
duced rates of adenine removal compared to wild-type 
MutY. The variants corresponding to G396D and Y179C, 
showing a 6-fold and 80-fold slower rate, respectively [49]. 
Also, considerably reduced binding affinities for G and 8-
oxo-G substrates were observed in the cases of both variants 
[49].  
  Functional studies of additional MUTYH mutations have 
also been conducted, although none as comprehensive as for 
Y179C or G396D, for which reason merely a short overview 
will be given in the present review: R182C, R182H, R185Q 
and G189E, all are located in the pseudo-HhH motif of the 
MUTYH catalytic domain, are considered to induce func-
tional MUTYH changes comparable to those observed in cell 
lines with Y179C variants [57, 69, 74, 75]. The missense 
variants P405L and A473D, both located in the C-terminal 
domain, are both supposed to have functional significance 
[67, 74]. 
  Functional analyses of two MUTYH mutations, which lie 
close to or within the MSH6-binding domain of the MUTYH 
gene, have been preformed: The variants R241W and V246F 
have preserved their ability to physically interact with 
MSH6, but both show reduced MUTYH function [54]. 
R245C, also located near the MSH6 binding domain, is 
likewise assumed to compromise the interaction between the 
MUTYH and MSH6 [55]. 
THE SIGNIFICANCE OF THE MUTYH GENE IN RE-
LATION TO THE DEVELOPMENT OF POLYPOSIS 
  Results from several studies indicate, that mutations in 
the MUTYH gene, more often than previously assumed, are 
the disease causing factor in Polyposis patients. Sieber and 
colleagues found, that an AFAP-like phenotype is more of-
ten caused by germline mutations in the MUTYH gene than 
in the APC gene [40]. Another study of patients with AFAP 
phenotypes, found APC germline mutations and MUTYH 
biallelic mutations in equal numbers of families [19]. Con-
sistent with these results, a study of CRC patients by Enholm 
et al. has suggested, that the contributions of germline muta-
tions in the APC gene and the MUTYH gene are fairly equal 
[84].  
  In studies of Polyposis patients (N=995), it has been 
found that 5-22% of the patients with 3-100 adenomas and 
7.5-17% of those with over 100 adenomas had biallelic mu-
tations in the MUTYH gene [19, 40, 85]. Furthermore, sev-
eral studies have found that none of the patients, who had 
biallelic germline MUTYH mutations (N=63), presented with 
a phenotype consistent with severe classical FAP, the criteria 
being: more than 1000 polyps or early-onset CRC (before 
the age of 50 years), and the development of more than 100 
polyps before the age of 35 years, respectively [40, 85, 86]. 
These results indicate that a higher proportion of AFAP-like 
phenotypes are caused by MUTYH mutations compared to 
FAP-like phenotypes. 
CLINICAL FEATURES OF MAP 
 Table  2 provides an overview of phenotypic characteris-
tics of MAP, using information gathered from different stud-
ies of MAP patients.  
MODE OF INHERITANCE  
  MAP is an autosomal recessive disease, caused by bialle-
lic mutations in the MUTYH gene. The majority of family 
histories of MAP patients were found to be consistent with a 
recessive inheritance, typically with affected siblings, but 
unaffected parents [19, 21, 38-40, 62, 65, 66, 68, 69, 74, 75, 
85-87]. Furthermore, Russel et al. found no MUTYH germ-
line mutations among Polyposis patients, who were negative 
for  APC germline mutations, and had a family anamnesis 
consistent with a dominant mode of inheritance [75]. In con-
trast, other studies have found family histories appearing to 
follow a dominant mode of inheritance among MAP patients 
in about 15-30% of the studied cases [68, 69, 74, 78, 85]. 
However, it is possible, that a recessive trait as MAP, due to 
a relatively high frequency of heterozygote mutation carriers 
in some populations, can mimic dominant inheritance, dis-MUTYH Associated Polyposis (MAP)  Current Genomics, 2008, Vol. 9, No. 6    427 
playing a pseudo-dominant mode of inheritance, especially 
in cases of parental consanguinity. On the other hand, some 
have proposed a co-dominant model for mode of inheritance, 
suggesting an increased CRC risk for monoallelic MUTYH 
germline mutation carriers compared to non-carriers, as will 
be discussed further [48, 57, 70, 71, 84, 88-92].  
  In studies of healthy controls, no unaffected individuals, 
who were homozygote for germline MUTYH mutations, have 
been found [57, 70, 71, 84, 90, 91] and Table 3. This indi-
cates that biallelic germline MUTYH mutations are highly 
penetrant. Accordingly, in a case-control study of CRC pa-
tients (N=2,239), all homozygote MUTYH carriers (N=12) 
developed CRC before the age of 60 years [92]. 
AGE AT TIME OF CLINICAL DIAGNOSIS OF MAP 
  The average age at time of clinical diagnosis among 
MAP patients is typically around 47 years (range: 13-72 
years, N=106) [19, 57, 62, 76, 77, 85-87] and Table 2. 
  Characteristically, the age at time of clinical diagnosis is 
higher among patients with biallelic MUTYH germline muta-
tions compared to Polyposis patients without MUTYH muta-
tions. This applies both to studied Polyposis patients with 
<100 adenomas [57, 65, 74] as well as to Polyposis patients 
with >100 adenomas, who are also negative for APC germ-
line mutations [40, 93]. In one of these studies (N= 58) this 
result was statistically significantly [74].  
  Because of the recessive mode of inheritance, the identi-
fication of MAP patients is complicated, as MAP patients 
often seem to be sporadic cases with no family history of the 
disease at clinical presentation. Consequently, most MAP 
patients are diagnosed due to symptoms and not as a result of 
prophylactic screening, unlike many FAP and AFAP patients 
[85]. In accordance to this, many MAP patients are also typi-
cally discovered at a later time in the course of their disease 
than other groups of Polyposis patients. For example, this 
can be illustrated by the higher proportion of MAP patients, 
who have already developed CRC at the time of their clinical 
diagnosis as compared to FAP patients (see later). 
DEVELOPMENT OF ADENOMAS  
  In several studies of Polyposis patients, the phenotypes in 
regard to the number of adenomas are generally seen to be 
more severe in MAP patients compared to the phenotypes of 
AFAP patients, but milder compared to those of classic FAP 
patients [40, 61, 68, 74, 85].  
  Characteristically, MAP patients develop between 10-
100 adenomas (Table 2), which is a smaller number than 
seen in the classic FAP phenotype. Several studies of Poly-
posis patients have all found the highest incidence of bialle-
Table 2.  Clinical Features of Identified MAP Patients  
 Sieber  et al. 
2003 
[40] 
Sampson et al. 
2003 
[62] 
Isidro et al. 
2004 
[69] 
Wang et al. 
2004 
[57] 
Nielsen et al. 
2005 
[87] 
Russell et al. 
2006 
[75] 
Number of MAP 
patients 
(Carriers of  
biallelic MUTYH 
mutations)  
 
N=14 
 
N=25 
 
N=21 
 
N=16 
 
N=40 
 
N=7 
Mean age at the  
time of clinical  
diagnosis 
For Patients with  
10-100  
adenomas:  
56 years 
Range: 45-59 
years 
For Patients with 
100-1000  
adenomas: 
48 years 
Range: 30-70 
46 years 
Range: 13-65  
years 
50 years 
Range: 36-68  
years 
47 years 
Range: 37-63  
years 
45 years 
Range: 21-67  
years 
48 years 
Range: 33-60  
years 
Number of colo-
rectal adenomas  
 
43%: Median: 55 
Range: 18-100 
57%: 
100-1000 
 
44%: 10-100 
36%: >100 
20%: Unspecified 
 
71%:10-100 
19%:100-1000 
5%: >1000 
 
19%: 20-49 
19%: 50-99 
25%: 100-500 
35%: Unspecified 
 
29%: 10-99 
42%: 
“Multiple” 
29% 100-1000 
  
<100 
(Only patients  
with 5-99  
adenomas were tested) 
In this table only studies in which the numbers of tested MAP patients are > 5 are included.  
The tested individuals are all APC germline mutation negative. The individuals tested are either probands or call-up patients with colorectal adenomas. 428    Current Genomics, 2008, Vol. 9, No. 6  Poulsen and Bisgaard 
lic MUTYH mutations in groups of patients with between 15-
100 adenomas [40, 57, 61, 69, 85]. In the applied studies, the 
incidences of biallelic MUTYH mutations in the groups of 
patients having 15-100 adenomas, were found to be between 
16-47% (N=835). However, none of the results were statisti-
cally significant.  
  In a recent study of AFAP patients (N=140), comparing 
the clinical features of patients with APC (N=93) and bialle-
lic MUTYH germline mutations (N=26), no significant dif-
ferences between the two groups were found [19]. However, 
this result might be biased due to the smaller sample size of 
the MAP patients compared to the patients with germline 
APC mutations. When compared to Polyposis patients with-
out mutations in neither the MUTYH nor the APC gene, 
MAP patients seemed to develop the lowest number of ade-
nomas, although no statistically significant results have been 
found [40, 77].  
  The morphology of the adenomas appears to be similar 
regardless of whether their occurrence is caused by germline 
mutations in the MUTYH or in the APC gene [40, 65]. Like-
wise, microadenomas have been found in patients with both 
genotypes [40, 46, 62].  
DEVELOPMENT OF CRC  
  In several studies of CRC patients (N=3,320), biallelic 
germline MUTYH mutations were found in 0.4-1.9% of all 
cases (Table 3). Based on these results, the contribution of 
biallelic MUTYH mutations to CRC seems to correspond to, 
Table 3.  The Frequencies of Carriers of MUTYH Germline Mutations Y179C and G396D Among CRC Patients and Back-Ground 
Populations 
 Enholm  et al.  
2003 
[84] 
Croitoru et al.  
2004 
[70] 
Fleischmann  
et al. 2004 
[71] 
Wang et al. 
2004 
[57] 
Peterlongo  
et al. 2005 
[91] 
Webb et al. 
2006 
[98] 
Küry et al. 
2007 
[41] 
Population 
group 
Finland 
 
Canada UK  USA  USA  UK  France 
Carriers of 
MUTYH  
germline  
mutations 
among CRC 
patients 
       
Number of 
tested  
individuals with 
CRC 
 
N =1042 
 
N=1238 
 
N =358 
 
N=444 
 
N=238 
 
N=2561  
 
N=1024 
Monoallelic 
carriers 
0.5 %  2.3 %  2.2 %  2.3 %  1.7 %  2.1%  2.3% 
Biallelic carriers  0.4 %  1.9 %  0.6 %  0.5 %  0.8 %  0.2%  0.1% 
Total percent-
age of carriers 
of MUTYH  
germline  
mutations 
0.9% 4.2% 2.8% 2.8% 2.5% 2.2% 2.4% 
Carriers of 
MUTYH  
germline  
mutations in 
back-ground 
populations 
 
 
  
 
    
Number of 
individuals 
tested 
 
N= 424 
 
N= 1255 
 
N=207* 
  
N=918 
 
N=2695  
 
N=1121 
Monoallelic 
carriers 
0  1.7%  1.9%  0.8%  2.11%  1.8% 
Biallelic carriers  0  0  0  0  0  0 
In this table only studies in which the numbers of tested individuals are > 50, are included. *Based on data from studies by Al-Tassan et al., 2002 and Sieber et al., 2003. MUTYH Associated Polyposis (MAP)  Current Genomics, 2008, Vol. 9, No. 6    429 
or even be greater than that of FAP, FAP accounting for less 
than 0.1% of all CRC cases, as found by Bülow [10].  
  In two other studies of CRC patients (N= 2,268), a sig-
nificant association between biallelic germline mutations in 
the  MUTYH gene and the development of CRC, has been 
determined [75, 92]. In one of these studies (N=2,239), MAP 
patients were found to have a 93-fold increased risk of de-
veloping CRC compared to a group of unaffected controls 
from the general population [92].  
  Among MAP patients, the average age of CRC onset is 
found to be 47 years (range: 29-72 years) [19, 62, 68, 75, 85, 
87]. The frequency of patients with a synchronous CRC at 
time of diagnosis is greater among MAP patients compared 
to among FAP patients [69, 74, 93]. These results comply 
with the fact that FAP patients generally are diagnosed ear-
lier than MAP patients, facilitated by the dominant mode of 
inheritance of FAP and the use of Polyposis Registers in 
many countries. Therefore, the prophylactic treatment of 
FAP prevents the development of CRC in a higher number 
of patients. As both probands and call-ups were included in 
the applied studies, and as none of the results were statisti-
cally significant, more specific studies examining only 
probands are needed.  
  There have been many inconsistent results regarding the 
typical location of carcinoma in MAP patients. Over-
representation of both right and left sided CRC has been 
demonstrated [19, 39, 46, 71, 74, 75, 87, 88]. Presumably, 
the location of CRC among MAP patients should not be con-
sidered important, as the prognosis seems to be independent 
of the CRC location [74]. 
ASSOCIATED CANCERS AND EXTRACOLONIC 
MANIFESTATIONS 
  The manifestation of other primary cancers than CRC or 
other extracolonic manifestations are less frequent among 
MAP patients compared to among FAP patients [74]. Sev-
eral studies have failed to report other cancers than CRC or 
any extracolonic features among the examined MAP patients 
[38, 40, 57, 61, 65, 66, 69, 71, 93]. The methods of clinical 
examination were not specified in the applied studies. For 
this reason, bias could be suspected, as patient information is 
often gathered from several different databases without as-
surance that all patients were systematically examined.  
  Conversely, several studies have described the occur-
rence of extracolonic features in MAP patients, mostly upper 
gastrointestinal lesions [37, 40, 62, 63, 74, 75, 78, 84-87, 94-
96], see Table 4. 
  However, these results should be regarded with reserva-
tions, as the numbers of examined MAP patients in the ma-
jority of the studies were very small. In addition, bias could 
result from a difference in the methods of investigation used 
in the individual studies, as these are only sparsely describe 
in most of the studies. Also, some of the reported extracolo-
nic manifestations were reported in very low frequencies 
among the examined MAP patients. They are therefore more 
likely to be present by chance, rather than being associated 
with biallelic MUTYH mutations.  
  The described findings suggest that extracolonic manifes-
tations are generally not a part of the characteristic MAP 
phenotype, but can occur. However, further studies with 
more systematic and thorough investigation of MAP patients 
are needed to address this issue.  
HETEROZYGOTE AND CRC RISK 
  At present, no conclusive evidence has been found, that 
monoallelic carriers of MUTYH germline mutations have an 
increased CRC risk compared to the general population. 
However, as seen in Table 3, percentages of carriers of 
monoallelic germline MUTYH mutations are generally larger 
among CRC patients, than the same percentages among the 
corresponding background populations. Furthermore, several 
studies have shown a tendency for a slightly elevated CRC 
risk [40, 41, 57, 62, 66, 70, 71, 85, 88, 90, 93, 97], especially 
in those over 55 years of age [41, 89, 92, 98]. However, res-
ervations towards these studies should be taken, as results 
from the mentioned studies have failed to be convincing, 
with merely one study achieving a slight statistical signifi-
cance [97]. Also, some of the mentioned studies have been 
criticized for the statistical methods used [98, 99], and meta-
analyses of the different studies have found inconsistent re-
sults [89, 98].  
  A suggested explanatory model for a possible association 
between monoallelic MUTYH mutations and a co-dominant 
mode of inheritance of CRC, is LOH of chromosome 1p, 
where the MUTYH gene in located, possibly representing an 
early event in CRC tumorgenesis [48, 70]. According to this 
model, loss of the wild-type MUTYH gene on 1p in monoal-
lelic MUTYH mutation carriers is likely to contribute to an 
increased CRC risk, as 1p LOH has been found in tumors 
from monoallelic MUTYH mutation carriers [48, 77]. In con-
trast, other studies that have investigated 1p LOH in tumors 
from monoallelic MUTYH mutation carriers have failed to 
find results of sufficient significance to support this theory 
[40, 84]. 
  On the other hand, Peterlongo et al. combined results 
from 9 case-control studies of CRC patients (Cases: N= 
2,707 and controls: N= 2,321), and were not able to demon-
strate a significant association between monoallelic carriers 
of MUTYH germline mutations and the development of CRC 
[91]. Consequently, as it –in the worst of cases- can only be 
a matter of a minimally increased CRC risk compared to the 
risk of the general population, it seems unlikely, that the ten-
dency for an increased CRC risk in heterozygote individuals 
is powerful enough to be of diagnostic or prophylactic im-
portance.  
  The exact role of monoallelic MUTYH germline muta-
tions in CRC tumorgenesis is still uncertain, but as men-
tioned earlier, interactions with other genes, for example a 
MMR gene, are possibly of significance.  
  In addition, several large studies of Polyposis patients 
have found frequencies of monoallelic MUTYH  mutation 
carriers that correspond fairly well to those of biallelic carri-
ers, see Table 5. 
  This indicates that monoallelic MUTYH germline muta-
tions may be associated with a Polyposis phenotype. How-
ever, as seen in Table 5, the reported frequencies of mono- 
and biallelic carriers vary considerably among studies. This 
is likely to be a result of differing inclusion criteria, as these 
are not thoroughly described in all of the applied studies. 430    Current Genomics, 2008, Vol. 9, No. 6  Poulsen and Bisgaard 
The significance of monoallelic MUTYH mutations needs to 
be assessed further in comparable studies on the subject. 
GENETIC COUNSELING AND PROPHYLAXIS 
  Frequently, MAP patients have already developed CRC 
at the time of clinical diagnosis, before prophylactic treat-
ment can be initiated. Genetic testing and counseling of indi-
viduals at risk of developing MAP, is essential for the future 
prospect of MAP patients, so that prophylactic screening can 
be initiated. In this context it is important that knowledge 
about the disease and mode of inheritance is continuously 
searched for and utilized for the organization of guidelines, 
which we believe will assure the best treatment for these 
patients.  
DETERMINATION OF THE GENOTYPE 
  Based on the recessive mode of inheritance most com-
monly seen in MAP families, siblings to an affected individ-
ual have a 25% a priori risk of disease. Consequently, deter-
mination of the genotype is especially important in these 
individuals [62, 75, 92]. In some MAP families, the mode of 
inheritance is pseudo-dominant, i.e. appears to be dominant 
although in reality recessive [19, 68, 74, 87].  
  In practice, it is important to search for germline muta-
tions in both the APC and the MUTYH gene. This applies to 
both individuals having a familiar disposition for multiple 
adenomas and/or CRC as well as in apparently sporadic 
CRC cases, if the clinical presentation gives hints of a Poly-
posis syndrome. In cases with a positive family anamnesis, 
the most probable mode of inheritance can guide the assess-
ment of which gene to start with, i.e. the APC or the MUTYH 
gene when a dominant mode or recessive mode is seen, re-
spectively [19]. 
  Furthermore, the characteristic mutations in specific 
populations makes it possible to target the MAP screening in 
accordance with ethnic background, thereby making the 
screening more efficient, when the background of the patient 
is known [57, 64].  
Table 4.  Extracolonic Manifestations Reported in MAP Patients 
Extracolonic Manifestation 
Number of MAP Patients (with 
Biallelic MUTYH Mutations)  
Examined 
Overall Percentage of MAP  
Patients with Extracolonic  
Manifestations 
Reported by 
Duodenal lesions 
(Adenomas and/or cancer) 
N= 154  13%   [40, 62, 74, 75, 77,  
85, 86, 87, 88, 94] 
Gastric lesions (Fundic gland pol-
yps or stomach cancer) 
N= 133  8%   [62, 85, 86, 87, 88] 
CHRPE (Congenital hypertrophy of 
the retinal pigment epithelium) 
N= 22  18%   [40, 93]  
Osteomas N=14  14%    [93] 
Desmiod cysts  N=14  7%   [93] 
Oesophageal cancer  N=16  6%   [87] 
Thyroid carcinoma  N= 57  4%   [85, 95] 
Breast cancer  N=22 (female MAP patients)*
1  18%   [87] 
Dental cysts   N=14  7%   [93] 
Tooth agenesis  N=7  14%   [78] 
Lipoma N=56  4%    [85] 
Multiple sebaceous adenomas   N=2 (case reports)  100%   [63, 95]  
Sebacous carcinoma  N=1*
2 (case reports)  100%   [37] 
Pilomatricomas  N=2 (case reports)  100%   [96] 
Melanoma N=4  25%    [84] 
Basocellular carcinoma of the skin  N=49  2%   [88] 
CNS carcinoma  N=55  4%  [77, 88] 
Leukemia N=6  17%    [77] 
Uterus cancer  N=49  2%   [88] 
*
1 An additional case of breast cancer in a biallelic MUTYH mutation carrier was reported by Olschwang et al. 2007, however no information on sex proportions in the examined 
MAP patients was reported [88].  
*
2 This Patient was found to have biallelic MUTYH mutations, although no colorectal adenomas were found at the age of 53 years old. However, one case of be early-onset CRC 
(before 50 years of age) was seen in the patient’s family. This patient had both endometrial cancer as well as sebaceous carcinoma [37]. MUTYH Associated Polyposis (MAP)  Current Genomics, 2008, Vol. 9, No. 6    431 
 As Y179C and G396D at present are the most frequently 
found mutations in Caucasian MAP patients, an obvious 
possibility would be to screen specifically for these in Cau-
casian individuals [65]. A disadvantage of such a selective 
screening is, that MAP patients, who are compound het-
erozygote for just one of these variants, or homozygote for 
other MUTYH variants, would be missed [57, 77, 86, 100]. 
Eliason et al. demonstrated an increased clinical sensitivity 
for the detection of MUYTH mutations in their study, when 
all exons and intron-exon boundaries of the MUTYH gene 
were screened, compared to the sole testing for Y179C and 
G396D [100]. Accordingly, all coding regions of the MU-
TYH gene should be screened in individuals found to be het-
erozygote for Y179C or G396D to establish their true genetic 
status [85, 86, 100]. Recently, Piccioli et al. have designed 
specific assays for detecting the 6 most frequently found 
MUTYH mutations using a multiplex T-ARMS-PCR method 
[101]. This method has been shown to be both accurate and 
inexpensive, and can furthermore be adapted according to 
the specific frequencies of MUTYH mutations in different 
population groups [101]. In patients presenting with an 
atypical MAP phenotype, i.e. <10 colorectal adenomas or 
familial mismatch repair proficient CRCs, van Puijenbroek 
et al. have proposed a prescreening method also considered 
to be cost-effective [102]. This method consists of the 
screening of tumors for KRAS2 c.34G > T, a somatic muta-
tion in the KRAS2 gene shown to be more common in MAP 
patients compared to sporadic CRC cases. This should be 
followed by screening for population specific MUTYH muta-
tions in cases positive for the aforementioned KRAS2 muta-
tion [102].  
  The frequencies of Y179C and G396D in the general 
population are low compared to the occurrence among MAP 
patients (Fig. (2) and (3)), and for this reason, there is at pre-
sent no indications for MAP screening of the general popula-
tion [75, 84, 85]. However, genetic testing of spouses of 
MUTYH mutation carriers to asses the genotype and corre-
sponding disease risk of offspring, has been recommended 
[77].  
PROPHYLAXIS AND TREATMENT 
  The prophylactic surveillance of MAP patients is recently 
reviewed by Vasen et al. in [16]. Here a surveillance proto-
col in accordance with the recommendations for AFAP pa-
tients is suggested [16]. However, some recommend begin-
ning at the age of 20-25 years, which is later compared to 
AFAP recommendations [19]. The surveillance of MAP pa-
Table 5.  MUTYH Germline Mutations Among Polyposis Patients who are Negative for APC Germline Mutations 
 
 
Sieber et al. 
2003 
[40] 
Sampson et al. 
2003 
[62] 
Isidro et al. 
2004 
[69] 
Wang et al. 
2004 
[57] 
Nielsen et al. 
2005 
[87] 
Russell et al. 
2006 
[75] 
Slová et al. 
2007 
[76] 
Kim et al.  
2007 
[61] 
Population 
group 
UK UK  Portugal  USA  The  
Netherlands 
Switzerland  Czech  
Republic 
Korea 
Number of 
non-related 
tested 
Polyposis 
patients*
1 
N=259 
(3 to >100) 
N =111 
(At least 10) 
N =53 
(10 to >1000) 
N=140 
(4 to >500) 
N=170 N=61 
(5-99) 
N= 82 
(3 to >100) 
N=62 
(10 to >100) 
Method of 
screening 
of the 
MUTYH 
gene 
All Exons  
and Exon- 
intron  
boundries 
Caucasians: 
Exon 7  
+13*
2,  
Hetero-
zygote/Non-
Caucasians:  
All exons 
All Exons  Exon 7 + 13  All Exons  Exon 7 + 13, 
if hetero-
zygote: all 
exons  
All Exons 
and Exon-
intron  
boundries 
All exons 
Carriers of 
monoallelic 
MUTYH 
germline 
mutations 
 
4 % 
 
 
3% 
 
0% 
 
3% 
 
24% 
 
10% 
 
1% 
 
5% 
Carriers of 
biallelic 
MUTYH 
germline 
mutations 
 
5 % 
 
 
23% 
 
40% 
 
11% 
 
24% 
 
10% 
 
2% 
 
3 % 
In this table only studies in which the numbers of tested individuals are > 50 are included. The tested individuals are all APC germline mutation negative. The individuals tested are 
either probands or call-up patients with colorectal adenomas. *
1 The groups of tested Polyposis patients included both patients with < and > 100 colorectal adenomas. The reported 
number of adenomas in the groups in question are given in brackets. *
2 The common mutations Y179C and G396D are found in exon 7 and 13, respectively. 432    Current Genomics, 2008, Vol. 9, No. 6  Poulsen and Bisgaard 
tients should consist of colonoscopy in two-yearly intervals 
as opposed to sigmoidoscopy in FAP patients, due to the 
often more attenuated phenotype and distal polyp location of 
MAP compared to FAP [16, 19]. Furthermore, upper gastro-
intestinal endoscopy starting from the age of 25-30 years is 
advised in MAP patients [16], even though the question of 
upper gastrointestinal endoscopy ought to be further investi-
gated in studies, more specifically researching extracolonic 
manifestations in MAP patients.  
  Naturally, the outlined recommendations should be ad-
justed according to the number, size and degree of dysplasia 
of the adenomas of the individual patient [57].  
  Since MAP patients typically develop less adenomas than 
FAP patients, the prophylactic treatment of MAP patients 
should as a starting point be aimed at colonoscopy with 
polypectomy. It could however be appropriate to apply 
colectomy in MAP patients developing a particularly large 
number or advanced adenomas [16, 19, 68]. 
GENETIC COUNSELING OF HETEROZYGOTE 
CARRIERS OF MUTYH GERMLINE MUTATIONS 
  In our judgment, there is no indication for prophylactic 
surveillance in heterozygote carriers of MUTYH germline 
mutations at the present time. However, we believe that rela-
tives at risk of developing MAP should be searched for on 
the basis of family anamnesis, if MUTYH  germline muta-
tions are discovered, in order for appropriate measures to be 
made on this basis. 
CONCLUSION AND FUTURE PERSPECTIVES 
  The full extent of the significance of MUTYH in the de-
velopment of CRC is yet to be resolved. Biallelic germline 
mutations in the MUTYH gene are found to be associated 
with a markedly increased risk of developing Polyposis and 
CRC. The interactions between MUTYH and the MMR sys-
tem could play a role in the CRC tumorgenesis in MAP pa-
tients.  
  At times, it can be difficult to distinguish between the 
phenotypes of FAP, AFAP, Lynch syndrome and MAP. As-
pects regarding phenotypic differences between MAP pa-
tients and other Polyposis patients form the base of the rec-
ommendations for counseling and prophylactic treatment of 
MAP patients, which is stated here. Germline mutations 
found in the MUTYH gene have shown a great ethnic vari-
ability, and further knowledge about this could be used to 
target the genetic screening of Polyposis patients towards 
specific population groups. Genetic screening for germline 
mutations in the MUTYH gene as well as in the APC gene 
should be performed on equal terms, perhaps guided by the 
most probable mode of inheritance. Prophylactic surveil-
lance of MAP patients could be colonoscopy with polypec-
tomy in mind from 20-25 years of age.  
  In the future, more MAP patients could be identified be-
fore developing CRC by establishing MAP registers and 
finding call-up patients based on family anamnesis, as it is 
currently done for FAP patients in many countries. In this 
way the future prospects of MAP patients could be improved 
markedly.  
SEARCH CRITERIA 
  The applied papers were all found in the PubMed data-
base using the following terms: MYH Associated Polyposis 
/MUTYH Associated Polyposis /MutYH Associated Poly-
posis. The search was only for material published in English 
and was made without time-limitation. All papers published 
between 01/01 2002 and 01/02 2008. We also searched ref-
erence lists of relevant papers. 
ABBREVIATIONS 
A =  Adenine 
AFAP  =  Attenuated Familial Adenomatous Poly-
posis 
APC =  Adenomatous  Polyposis  Coli 
BER =  Base  Excision  Repair 
C =  Cytosine 
CRC =  Colorectal  Cancer 
FAP  =  Familial Adenomatous Polyposis 
G =  Guanine 
HhH =  Helix-Hairpin-Helix 
HNPCC  =  Hereditary Non-Polyposis Colorectal 
Cancer 
LOH  =  Loss of Heterozygosity 
LOVD  =  Leiden Open Variation Database 
MAP =  MUTYH Associated Polyposis 
MMR =  Mismatch  Repair 
MSI =  Microsatellite  Instability 
MUTYH gene  =  MYH gene = MutY Human Homolog 
gene 
ROS =  Reactive  Oxygen  Species 
8-oxoG =  8-oxo-7,8-dihydroxy-2´-deoxyguano-sine 
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